XingImaging 1589-EDIT REV

History

XingImaging was founded in 2018 by Drs. Tamagnan, Chan, Marek, and Seibyl to create a unique clinical research company that combines excellence in clinical neurology/neuropsychiatry with state-of-the-art imaging using custom radiopharmaceuticals for diagnosis and monitoring of neurodegenerative and neuropsychiatric disorders. This fusion of internationally recognized expertise in the clinical and imaging arenas into a unified research-dedicated organization allows XingImaging to efficiently develop and execute clinical trials for diagnosis, progression, and disease monitoring trials that emphasize quantitative imaging outcome measures.

XingImaging is a clinical PET imaging service company that offers end to end support of radiopharmaceutical imaging trials. XingImaging’s services include radioligand development, radioligand production, design and implementation of clinical imaging trials utilizing PET, and customized clinical imaging center coordination and management in multicenter imaging studies. 

Primary Areas of Expertise

XingImaging has two related business areas of expertise:

Translational Research

Development and application of radioligands for both early drug development and/or to investigate disease pathobiology.

Clinical Multi-Center

Clinical multi-center imaging core lab services to apply radioligands in multi-center studies for subject eligibility and/or disease monitoring.

Translational Research and Clinical Imaging Solutions

XingImaging has developed a highly efficient and focused translational research model for radioligand evaluation, enabling us to rapidly and efficiently screen candidate radioligands, moving promising radioligands from chemistry to preclinical and human proof of concept (POC) studies so that these radioligands may be applied to drug development or clinical questions. XingImaging has the expertise to offer radiochemistry support as needed both for its translational research studies and to ensure the quality of radiochemistry production and distribution in multi-center studies. XingImaging also provides comprehensive, coordinated clinical research strategies for the application of imaging tracers in multi-center clinical trials.

In 2023, XingImaging, and MITRO Biotech Co., Ltd., each highly recognized for drug development and imaging solutions, joined forces to provide services across the pre-clinical and clinical spectrum including radioligand development and manufacturing, design and implementation of Phase 1 to Phase 4 clinical trials, and customized clinical imaging site coordination and management in multi-site imaging studies. 

XingImaging 1543-EDIT REV

Management Team

Person wearing blue shirt and glasses

Gilles Tamagnan, PhD

Chief Executive Officer

Dr. Tamagnan is an Associate Professor Adjunct, Department of Psychiatry, and the CEO of XingImaging and Research Scientist at Xuanwu Hospital in Beijing. Dr. Tamagnan provides leadership and expert knowledge to colleagues to design and coordinate experiments for radiolabeling the tracers and for developing them into a radiopharmaceutical suitable for human administration. He is also responsible of the IND submission and working with the clinical team to validate the radiopharmaceutical. He has over 20 years of industrial and academic experience in the research and development of radiopharmaceuticals labeled with short-lived gamma-emitting radionuclides. Dr. Tamagnan is an active member of the nuclear medicine research community over the past 20 years and has been involved in the evaluation of over 70 CNS PET and SPECT imaging agents in human aimed at the development of improved diagnosis and treatment of neurologic and psychiatric conditions. He is a physician sponsor of over 35 INDs.

Learn More
Person with gray hair posing confidently

Roger Gunn, PhD

Chief Science Officer

Dr. Gunn is an Emeritus Professor of Molecular Neuroimaging in the Division of Brain Sciences at Imperial College London and CSO of XingImaging. Dr. Gunn is an international expert on imaging for disease understanding and drug development. He has combined a career in academia (McGill University, Oxford University and Imperial College) and industry (GSK, Imanova, Invicro and XingImaging) holding Chief Science Officer positions for the last 15 years with responsibility for large scientific imaging portfolios. He has published over 200 peer reviewed papers in the field of imaging and drug development with an H-index of 75 and has delivered over 80 invited lectures. His career has involved positions on research councils, consultancy to pharmaceutical companies and the training and mentoring of PhD students and clinical research fellows. As Chief Science Officer at XingImaging he is heading the companies R&D of new biomarkers & analytics and leading the design, analysis and delivery of preclinical & clinical imaging trials for pharmaceutical companies.

Learn More
Woman in formal attire with crossed arms

Zhuqin (Kitty) Gu, MD PhD

General Manager & Director Operations - China

Dr. Gu has over 15 years of experience in clinical studies on early prediction and management of Parkinson's disease. She worked as project manager for multiple national and international cooperation projects, including MJFF projects, and played an important role in the setup and management for the first clinical center and specialist training system on Parkinson’s disease & Movement disorders in China. In 2018, Dr. Gu joined XingImaging China, started to build up the National PET network in China, and set up the standardized SOP for clinical operations for PET studies.

Learn More

Scientific Advisors

Default profile avatar illustration

Piu (Bill) Chan, M.D. Ph.D.

Dr. Chan is well known for his translational research on neurodegenerative disorders and other age-related disorders. Collaborating with Dr. Carlie Tanner on several unique cohorts, they were the first reporting that environmental exposures are the major risk factors for Parkinson’s disease. He has worked on developing models for CNS diseases including non-human primate models of Parkinson’s disease and dyskinesia. He has been studying familial and susceptibility genes and a variety of biomarkers for Parkinson's and Alzheimer's diseases in a few unique cohorts in China aimed for prediction and prevention of neurodegenerative diseases. Dr. Chan is the committee member for the MDS “Task Force on the definition of Parkinson’s disease” and “Telemedicine Task Force”. Dr. Chan’s team has participated in the International LRRK2 Consortium and Apple’s mPower projects. Dr. Chan has published more than 240 SCI peer-reviewed papers and about 350 peer-reviewed Chinese papers and served as editorial members of more than 15 international and Chinese journals.

Learn More
Default user profile silhouette

Kenneth Marek, M.D.

Dr. Marek is a neurologist with widespread expertise in neurodegenerative disorders. He is internationally recognized as an expert in imaging of neurodegenerative disorders and has made significant contributions to early detection and diagnostic use of radiotracers for these disorders for PD, AD, HD and other disorders. He has developed novel clinical design for brain imaging studies and has been the Principal Investigator in several multicenter trials including PPMI and PARS. 

Learn More
Blank user avatar image

John Seibyl, M.D.

Dr. Seibyl is an international expert on PET and SPECT imaging for neurodegenerative disorders. He is past President of the Brain Imaging Council of the Society of Nuclear Medicine. Dr. Seibyl is dually-boarded in Nuclear Medicine and Psychiatry and has twenty years of experience in clinical studies. He has made significant contributions to development of visual and quantitative analysis for PET imaging in neurodegenerative and neuropsychiatric disorders. Along with Dr. Marek he has directed and continues to direct several international multicenter imaging studies. Dr. Seibyl is an author on over one hundred publications on CNS imaging. 

Learn More
XingImaging 1677-EDIT REV

Our Commitment to Quality

XingImaging takes great pride in delivering high-quality services. We believe that compliance with regulations and continuous improvement of our processes will benefit you as well as the business.

Within XingImaging we are committed to:

  • Provide our sponsors with satisfaction in all services
  • Provide compassionate and confidential care to our research participants
  • Compliance with laws and regulations pertaining to the quality and safety requirements in all countries in which our services are offered
  • Continual improvement in the effectiveness of XingImaging's Quality Program
  • These commitments will be met through documented and reviewed quality objectives, commitment to performance, and unyielding integrity

Purpose, Vision, and Scientific Integrity

Minimalist hummingbird illustration on black background

Mission

XingImaging advances scientific discovery by delivering high-quality imaging and research services that support innovation, accuracy, and regulatory excellence across clinical and preclinical studies.

Modern hummingbird icon on black background

Vision

XingImaging aims to be a trusted global partner in imaging sciences, recognized for technical leadership, collaborative research, and reliable data-driven solutions.

Stylized bird logo with colorful wings

Values

XingImaging is guided by scientific integrity, quality-driven processes, teamwork, accountability, and a commitment to advancing research that improves human health.

Meet Our Leadership Team